Merck Says KEYTRUDA (pembrolizumab) Met Primary Endpoint Of Disease-Free Survival (DFS) In Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
Portfolio Pulse from Benzinga Newsdesk
Merck has announced that its drug KEYTRUDA (pembrolizumab) has met its primary endpoint of Disease-Free Survival (DFS) in certain patients with Muscle-Invasive Urothelial Carcinoma (MIUC) after surgery.
October 05, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's KEYTRUDA has shown positive results in patients with MIUC, potentially leading to increased demand for the drug.
The positive results from the trial indicate that KEYTRUDA is effective in treating MIUC, which could lead to increased demand for the drug. This could potentially boost Merck's revenues and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100